{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:12:20Z","timestamp":1792800740271,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.hfc.2022.02.005","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T19:18:54Z","timestamp":1655407134000},"page":"479-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cardiac Amyloidosis"],"prefix":"10.1016","volume":"18","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hfc.2022.02.005_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light Chain (AL) Amyloidosis: The Journey to Diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"issue":"16","key":"10.1016\/j.hfc.2022.02.005_bib2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/eurheartj\/ehz057","article-title":"Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis","volume":"40","author":"van den Berg","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hfc.2022.02.005_bib3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijcard.2018.03.088","article-title":"Biventricular assessment of light-chain amyloidosis using 3D speckle tracking echocardiography: Differentiation from other forms of myocardial hypertrophy","volume":"271","author":"Vitarelli","year":"2018","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.005_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.005_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hfc.2022.02.005_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","article-title":"Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy","volume":"300","author":"Maurizi","year":"2020","journal-title":"Int J Cardiol"},{"issue":"sup1","key":"10.1016\/j.hfc.2022.02.005_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13506129.2019.1582481","article-title":"The epidemiology of amyloidosis in Australia","volume":"26","author":"Wisniowski","year":"2019","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15955","article-title":"Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers","volume":"186","author":"Rezk","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s12265-019-09895-0","article-title":"Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome","volume":"12","author":"Zegri-Reiriz","year":"2019","journal-title":"J\u00a0Cardiovasc Transl Res"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.005_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","article-title":"Wild-type transthyretin-derived amyloidosis in various ligaments and tendons","volume":"42","author":"Sueyoshi","year":"2011","journal-title":"Hum Pathol"},{"issue":"47","key":"10.1016\/j.hfc.2022.02.005_bib12","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.005_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.recesp.2020.05.027","article-title":"Association between aortic stenosis and hereditary transthyretin amyloidosis","volume":"74","author":"Ripoll-Vera","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib14","article-title":"Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis","volume":"9","author":"Kim","year":"2019","journal-title":"Sci"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/17843286.2018.1461179","article-title":"Amyloid cardiomyopathy: a hidden heart failure cause that is often misdiagnosed","volume":"73","author":"Tung-Chen","year":"2018","journal-title":"Acta Clin Belg"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.005_bib16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and Extracellular Volume in Transthyretin Amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib17","first-page":"618","article-title":"Diagnostic performance of PET for detection of cardiac amyloidosis: A systematic review and meta-analysis","volume":"76","author":"Kim","year":"2020","journal-title":"J\u00a0Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"14","key":"10.1016\/j.hfc.2022.02.005_bib19","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2014-11-609883","article-title":"A\u00a0practical approach to the diagnosis of systemic amyloidoses","volume":"125","author":"De Larrea CF","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.005_bib20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.005_bib22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I) cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib23","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","article-title":"Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms","volume":"12","author":"Goto","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hfc.2022.02.005_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: A systematic investigation of 117 patients","volume":"119","author":"Schonland","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hfc.2022.02.005_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","volume":"99","author":"Vrana","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cjp2.126","article-title":"The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis","volume":"5","author":"Rezk","year":"2019","journal-title":"J\u00a0Pathol Clin Res"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.005_bib27","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.005_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10554-018-01524-2","article-title":"Left ventricular assessment in patients with systemic light chain amyloidosis: a 3-dimensional speckle tracking transthoracic echocardiographic study","volume":"35","author":"Pradel","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.005_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jcmg.2016.04.008","article-title":"Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System","volume":"10","author":"Barros-Gomes","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","article-title":"Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis","volume":"13","author":"Pan","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2022.02.005_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","article-title":"Digoxin Use in Cardiac Amyloidosis","volume":"133","author":"Donnelly","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2022.02.005_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2020.01.002","article-title":"Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter","volume":"222","author":"Loungani","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2022.02.005_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.hfc.2022.02.005_bib34","article-title":"Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients With Amyloid Cardiomyopathy","volume":"9","author":"Higgins","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.005_bib35","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41409-019-0440-5","article-title":"High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators","volume":"54","author":"Phull","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.005_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.healun.2013.01.987","article-title":"Left ventricular device implantation for advanced cardiac amyloidosis","volume":"32","author":"Swiecicki","year":"2013","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"12","key":"10.1016\/j.hfc.2022.02.005_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.47102\/annals-acadmedsg.V48N12p435","article-title":"Ventricular Assist Device Support in End-Stage Heart Failure From Cardiac Amyloidosis","volume":"48","author":"Lim","year":"2019","journal-title":"Ann Acad Med Singap"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.005_bib38","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jch.13619","article-title":"Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients","volume":"21","author":"McDonell","year":"2019","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.005_bib39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10741-019-09776-3","article-title":"Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement","volume":"24","author":"Rigopoulos","year":"2019","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.hfc.2022.02.005_bib42","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.005_bib43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/17512433.2019.1635008","article-title":"Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Gertz","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.hfc.2022.02.005_bib44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J\u00a0Card Fail"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib46","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A\u00a0human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In\u00a0Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib48","first-page":"186","article-title":"The prognostic value of baseline serum free light chain in cardiac amyloidosis","volume":"55","author":"Zhao","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26025","article-title":"Involved free light chains <10 mg\/L with treatment predict better outcomes in systemic light-chain amyloidosis","volume":"96","author":"Godara","year":"2021","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.hfc.2022.02.005_bib50","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A\u00a0prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bjh.15717","article-title":"Grading cardiac response in AL amyloidosis: implications for relapse and survival","volume":"186","author":"Eckhert","year":"2019","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.hfc.2022.02.005_bib53","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hfc.2022.02.005_bib54","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.bbmt.2019.04.024","article-title":"Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved","volume":"25","author":"Al Saleh","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hfc.2022.02.005_bib55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41375-020-1006-7","article-title":"Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis","volume":"35","author":"Szalat","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.hfc.2022.02.005_bib56","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2018-07-865857","article-title":"Beyond NEOD001 for systemic light-chain amyloidosis","volume":"132","author":"Varga","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.005_bib57","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hfc.2022.02.005_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.transproceed.2020.08.020","article-title":"Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience","volume":"53","author":"Chen","year":"2021","journal-title":"Transpl Proc"},{"issue":"10","key":"10.1016\/j.hfc.2022.02.005_bib59","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1111\/ajt.15487","article-title":"Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis","volume":"19","author":"Trachtenberg","year":"2019","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.hfc.2022.02.005_bib60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","article-title":"Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation","volume":"8","author":"Barrett","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.hfc.2022.02.005_bib61","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.hfc.2022.02.005_bib62","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171362200006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171362200006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:43:06Z","timestamp":1761554586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171362200006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S155171362200006X"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.005","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2022.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}